MedEx answers any queries you might have regarding Lenalidomide-5 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Lenalidomide 5 mg was approved in the US, the EU and Switzerland for use as a combined therapy in combination with dexamethasone in patients with multiple myeloma who have already received standard therapy. Since late 2005, Lenalidomide has been approved for using in the United States to treat patients in need of transfusion with patients with myelodysplastic syndrome, from groups with “low” or “intermediate-1” risk and simultaneous deletion of 5q chromosome with or without additional cytogenetic abnormalities.
Lenalidomide 5 mg refers to substances of class IMiDs. This abbreviation is used to refer to immunomodulating remedies, identifying pharmaceutical agents that can modulate the immune system. IMiDs are compounds derived from thalidomide that have a much lower number of side effects with identical or improved efficacy.
Today the mechanism of Lenalidomide has not been fully studied. Nevertheless, it is known that this substance affects various parts of the body. Immunomodulating and anti-angiogenetic properties of this substance affect the release of inflammatory substances and increase the production of anti-inflammatory substances. Inhibition of the formation of tumors in blood vessels. As a result, the supply of cancer cells with nutrients is deteriorating. Lenalidomide also has a direct effect on tumor cells by inhibiting their growth. So, Lenalidomide can correct metabolic processes that become unbalanced in different parts of the body.
However, Lenalidomide 5 mg therapy also has side effects. In many cases, when Lenalidomide is used, the pattern of blood changes temporarily. The number of both platelets (thrombocytopenia) and white blood platelets may decrease (neutropenia). Blood test data may indicate the need to discontinue therapy or reduce the dose of Lenalidomide. Some patients need growth factors and / or blood transfusions.
Another side effect of Lenalidomide may be an increased risk of blood clots during treatment (venous thrombosis and pulmonary embolism). Today there is no studies have been carried out clearly demonstrating that preventive therapy reduces the likelihood of thrombosis. Nevertheless, the doctor can prescribe prophylactic therapy for patients with vein thrombosis or pulmonary embolism, depending on the individual risk of blood clots. Other side effects that can be caused by taking Lenalidomide are diarrhea, skin rash and itching.